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Block of nicotinic acetylcholine 
receptors by philanthotoxins 
is strongly dependent on their 
subunit composition
Hamid S. Kachel1,†, Rohit N. Patel1, Henrik Franzyk2 & Ian R. Mellor1
Philanthotoxin-433 (PhTX-433) is an active component of the venom from the Egyptian digger 
wasp, Philanthus triangulum. PhTX-433 inhibits several excitatory ligand-gated ion channels, and 
to improve selectivity two synthetic analogues, PhTX-343 and PhTX-12, were developed. Previous 
work showed a 22-fold selectivity of PhTX-12 over PhTX-343 for embryonic muscle-type nicotinic 
acetylcholine receptors (nAChRs) in TE671 cells. We investigated their inhibition of different neuronal 
nAChR subunit combinations as well as of embryonic muscle receptors expressed in Xenopus oocytes. 
Whole-cell currents in response to application of acetylcholine alone or co-applied with PhTX analogue 
were studied by using two-electrode voltage-clamp. α3β4 nAChRs were most sensitive to PhTX-343 
(IC50 = 12 nM at −80 mV) with α4β4, α4β2, α3β2, α7 and α1β1γδ being 5, 26, 114, 422 and 992 times 
less sensitive. In contrast α1β1γδ was most sensitive to PhTX-12 along with α3β4 (IC50 values of 
100 nM) with α4β4, α4β2, α3β2 and α7 being 3, 3, 26 and 49 times less sensitive. PhTX-343 inhibition 
was strongly voltage-dependent for all subunit combinations except α7, whereas this was not the case 
for PhTX-12 for which weak voltage dependence was observed. We conclude that PhTX-343 mainly acts 
as an open-channel blocker of nAChRs with strong subtype selectivity.
Philanthotoxin-433 (PhTX-433; Fig. 1) is a polyamine-based toxin found in the venom of the Egyptian dig-
ger wasp, Philanthus triangulum, used to paralyse insect prey by inhibiting nicotinic acetylcholine receptors 
(nAChRs) and ionotropic glutamate receptors (iGluRs)1,2. It is structurally characterized by a central tyrosine res-
idue linked via amide bonds to a butyryl chain on one side and to a thermospermine moiety on the other (Fig. 1). 
This results in a molecule with a relatively bulky and hydrophobic head group and a positively charged (+ 3) tail at 
physiological pH. Apart from its inhibitory action on insect nAChRs and iGluRs, PhTX-433 and its closely related 
synthetic analogue, PhTX-343 (Fig. 1), also exhibit potent activity at vertebrate ionotropic receptors, and their 
receptor interactions have been quite extensively characterized for mammalian iGluRs, including the AMPA, 
kainate and NMDA receptor subtypes3–6, as well as for vertebrate muscle-type nAChRs7,8. These investigations 
have inferred that philanthotoxins (PhTXs) display some selectivity towards iGluRs over nAChRs.
Based on the observation that in both ionotropic receptor types the inhibition by PhTX-343 is use- and 
voltage-dependent (i.e. more potent inhibition is observed with increasing negative membrane potentials), it 
has been proposed that the dominant mode of action involves an open-channel blocking mechanism whereby 
the polyamine tail penetrates deep into the channel pore where the environment is hydrophilic, while the head 
group interacts with the more hydrophobic outer parts of the pore9–11. In AMPA receptors this is inferred by the 
observation that receptors lacking the GluA2 subunit are highly sensitive to PhTX-343, whereas those contain-
ing GluA2 are almost insensitive12. This is due to a single amino acid substitution caused by RNA editing at the 
so-called “Q/R site” that is located within the pore and forms the selectivity filter9.
Strong receptor selectivity was first realized following the development of an analogue in which the two 
secondary amine functionalities in PhTX-343 (and PhTX-433) were exchanged for methylene groups thereby 
generating PhTX-12 (Fig. 1). As expected PhTX-12 displayed significantly reduced potency at AMPA receptors 
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and slightly reduced potency at NMDA receptors, but unexpectedly exhibited increased potency at muscle-type 
nAChRs5,13. However, the latter finding was associated with a change in mode of action whereby the inhibition 
was weakly voltage-dependent, remaining strong at positive membrane potentials8,11.
Interestingly, there is a notable gap in our knowledge of ionotropic receptor inhibition by PhTXs regarding 
their action on mammalian neuronal-type nAChRs. Only a single study has investigated the effects of PhTX-343 
at nAChRs expressed by PC12 cells, showing that it potently antagonised responses to ACh in a voltage-dependent 
manner14.
In the present work, we investigated the inhibitory actions of PhTX-343 and PhTX-12 on some established 
subtypes of neuronal nAChRs comprising α 4β 2, α 3β 4, α 7, α 4β 4 and α 3β 2, by expression in Xenopus oocytes 
and voltage clamp recording. Also, we included embryonic muscle-type receptors (α 1β 1γ δ ) in our study to facil-
itate comparison to our previous studies with TE671 cells. We aimed to explore whether PhTXs can be used as 
subtype-selective inhibitors of nAChRs.
Materials and Methods
Reagents and nucleic acids. ACh was from Sigma. PhTX-343 and PhTX-12 were synthesized as described 
previously15.
cDNA clones of rat neuronal nAChR subunits (α 3, α 4, β 2 and β 4) and mouse muscle subunits (α 1, β 1, γ and δ ) 
were from the Salk Institute for Biological Studies (Professor Stephen Heinemann). The human α 7 and RIC-3 
cDNAs were provided by Professor David Sattelle (University College London). The β 2(V253F) and β 4(F255V) mutant 
subunit cDNAs were a kind gift from Dr. Cecilia Borghese, University of Texas at Austin.
Plasmids were linearized and cRNA transcribed using an mMessage mMachine kit (Ambion).
Xenopus oocyte preparation and injection. Oocytes isolated from mature female Xenopus laevis were 
supplied by the European Xenopus Resource Centre, University of Portsmouth, UK. Oocytes were treated with 
collagenase (0.5 mg/ml, Sigma type 1 A) in Ca2+-free solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM 
HEPES, 2.5 mM Na-pyruvate, 100 U/mL penicillin, 0.1 mg/mL streptomycin, pH 7.5) with shaking at 19 °C to 
defolliculate and remove the connective tissue surrounding the cells. After separation, oocytes were washed 
7 times with modified Barth’s solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, 
2.5 mM Na-pyruvate, 0.5 mM theophylline, 50 μ g/mL gentamicin, pH 7.5) and kept at 19 °C in the same solution.
Healthy oocytes were injected with cRNA using a Nano-liter Injector (World Precision Instruments Inc, USA). 
Mixtures of nAChR subunit cRNAs were injected as follows; for heteromeric rat neuronal receptors a 1:1 ratio of 
α :β at 200 ng/μ L; for mouse embryonic muscle a 1:1:1:1 ratio of α :β :γ :δ at 25 ng/μ L; human α 7 at 100 ng/μ L was 
mixed with RIC-3 at 30 ng/μ L. Each oocyte was injected with 50 nL of RNA solution. Injected oocytes were saved 
Figure 1. Structures of the naturally occurring PhTX-433 from Philanthus triangulum as well as of the two 
synthetic analogues, PhTX-343 and PhTX-12, used in this study. The numbers indicate the carbon spacing 
between nitrogen atoms in the polyamine moiety.
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in Barth’s solution at 19 °C for two to three days for expression of the target protein. During this time oocytes were 
regularly checked to remove unhealthy ones.
Electrophysiology. Electrophysiological recordings were taken from nAChR-expressing oocytes by 
two-electrode voltage clamp using a Geneclamp 500 voltage clamp amplifier (Axon instruments, USA). An 
oocyte was placed in the perfusion chamber using a plastic Pasteur pipette and the bath was perfused (~5 mL/
min) with fresh Frog Ringer solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2 and 5 mM HEPES, pH 7.5). 
Microelectrodes were pulled from borosilicate glass capillaries (Harvard GC150TF-10) using a programmable 
micropipette puller (Sutter P97, USA), and they had resistances between 0.5 and 2.5 MΩ when filled with 3 M 
KCl. The oocyte was voltage-clamped at holding potentials (VH) between − 60 and − 100 mV. ACh was consist-
ently used as the agonist, and it was applied without or together with PhTX analogues via an 8-channel perfusion 
system (Automate, USA) for 1 min to allow for equilibration of the current. Currents were recorded to a PC via 
a digidata 1200 analog-to-digital converter (Axon Instuments, USA) using WinEDR v3.2.6 Software (Dr John 
Dempster, University of Strathclyde, UK).
Data analysis. WinEDR was used to measure the current amplitude of responses to ACh at the ini-
tial peak and at the end of the one-minute application (“late” current). Data were normalized as % control 
response for PhTX inhibition or % maximum response for ACh agonism. Graphpad Prism 6 was used for data 
analysis, graph plotting and curve fitting. All plotted points are the mean ± SEM obtained from 4–20 oocytes. 
Concentration-inhibition and concentration-response curves were used to estimate IC50 and EC50 values for 
PhTXs and ACh, respectively, by using the following equations:
=
+ −
% control response 100
1 10 (1)Log PhTX LogIC nH( [ ] )50
=
+ −
M% maximum response
1 10 (2)LogEC Log ACh nH( [ ] )50
where M is the maximum response and nH is the Hill slope. IC50s and EC50s were compared for significant differ-
ences using an extra sum of squares F-test in Graphpad Prism 6.
Results
Sensitivity of nAChR subtypes to ACh. Oocytes expressing each subunit combination were exposed to 
ACh at concentrations between 10−8 M and 10−3 M (10−2 M for α 7) to obtain EC50 values (Table S1). Based on peak 
currents, receptors containing α 4 or α 1 subunits showed the highest sensitivity to ACh (EC50 values of ~10 μ M), 
α 3β 2 had intermediate sensitivity, while α 3β 4 and α 7 displayed lower sensitivity (EC50s > 100 μ M). In all cases 
EC50 values were slightly lower (1.4- to 6.7-fold) for late current, but a similar pattern of relative sensitivity 
emerged. These EC50 values demonstrate that, at least for α 4β 2 and α 3β 4 where data are available, the dominant 
subunit stoichiometries are (α 4/2)2(β 2/4)316,17. Further experiments analysing the effects of PhTX-343 and PhTX-
12 on the different nAChR subtypes were conducted by using approximate EC50 concentrations of ACh as follows: 
10 μ M for α 4β 2, α 4β 4, and α 1β 1γ δ , 30 μ M for α 3β 2, and 100 μ M for α 3β 4 and α 7.
Subtype selectivity of PhTX-343 and PhTX-12 inhibition. Xenopus oocytes expressing functional 
α 4β 2, α 4β 4, α 3β 4, α 3β 2, α 7 and α 1β 1γ δ nAChRs were used to investigate the relative inhibitory potencies of 
PhTX-343 and PhTX-12. The highest concentration (100 μ М) of each PhTX used in this study was first applied 
alone (at VH = − 80 mV) to oocytes expressing nAChRs, and this did not produce any effect on membrane cur-
rent. Co-application of PhTX-343 or PhTX-12 with ACh inhibited the current of each subtype of nAChR in a 
concentration-dependent manner (Fig. 2). Inhibition of the “late” current (1 min after the start of ACh applica-
tion) was always greater than that of the initial peak current. IC50 values for inhibition of each nAChR subtype by 
PhTX-343 and PhTX-12 are given in Tables 1 and 2, respectively.
PhTX-343 inhibition of nAChRs seemed to depend mostly on the type of β -subunit present, with receptors 
containing β 4 being most susceptible to the toxin. The ranking by degree of inhibition of ACh responses was: 
α 3β 4 > α 4β 4 > α 4β 2 > α 3β 2 > α 7 > α 1β 1γ δ with the potency at α 3β 4 (IC50 = 12 nM) being 1000 times higher 
than at α 1β 1δ γ (IC50 = 12 μ M) for late current at − 80 mV. For PhTX-343 the IC50 values for peak and late cur-
rent inhibition of α 4β 4 were roughly 3-fold and 5-fold, respectively, lower than those found for α 4β 2 nAChRs. 
Likewise, the potency of PhTX-343 on α 3β 4 nAChRs was higher by 115-fold on peak current and 137-fold on late 
current as compared to α 3β 2 (at − 80 mV). To investigate the possible cause of this high affinity of PhTX-343 for 
β 4-containing over β 2-containing nAChRs, we compared the amino acid sequence of the M2 domains of both 
β -subunits (Fig. 3), since previous observations indicated that PhTX-343 most likely interacts with this region11. 
This analysis showed only a single amino acid variation within this domain: V at position 253 in β 2 being substi-
tuted by F at the equivalent position (255; shaded orange in Fig. 3) in β 4. To test whether this might be responsible 
for the observed difference in affinities for PhTX-343 we tested nAChRs containing either β 2(V253F) or β 4(F255V). 
As expected, for α 4β 2(V253F) a 2.6-fold reduction (p = 0.049) in late current IC50 was observed as compared to 
α4β 2 (Fig. 4B), but there was no significant change in the peak current value (Fig. 4A). However, we did not see 
the expected increase in late current IC50 value for α 3β 4(F255V) as compared to that of α 3β 4 (12 nM at − 80 mV in 
both cases; Fig. 4B), and for the peak current the IC50 was even 2.1-fold reduced (p < 0.0001; Fig. 4A). These data 
suggest some involvement of F255 in β 4 in conferring high PhTX-343 affinity, but clearly other factors contribute 
to PhTX-343 binding. Finally, homomeric α 7 nAChRs with no β subunits and muscle-type nAChRs (α 1β 1γ δ) 
which contain more than one type of non-α subunit, were the least potently inhibited by PhTX-343.
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PhTX-12 inhibition of nAChRs did not show any clear pattern of dependence on specific α - or β -subunits. 
Similar to PhTX-343, PhTX-12 was most potent at α 3β 4 receptors, and it showed low potency at α 7 receptors 
(lowest potency in this case), but in contrast to PhTX-343 it was as potent at muscle-type receptors (α 1β 1δ γ ) as 
α3β 4 receptors. However, the range of PhTX-12 IC50 values was narrower than found for PhTX-343; there was only 
Figure 2. (A,B) Responses to ACh in the absence (black) or presence (blue) of 1 μ M PhTX-343 (A) or PhTX-12 
(B) for all of the tested nAChR subtypes. (C,D) Concentration-inhibition curves for PhTX-343 (C) and PhTX-12 
(D) inhibition of α 3β 4 (red ▲ ), α 4β 4 (blue ■ ), α 4β 2 (green ● ), α 3β 2 (brown ▼ ), α 7 (purple ◆) and α 1β 1γ δ  
(orange ×) peak (upper) and late (lower) current. The ACh concentrations were 10 μ M for α 4β 4, α 4β 2 and 
α1β1γδ , 30 μ M for α 3β 2, and 100 μ M for α 3β 4 and α 7. VH = − 80 mV. Curves are fitted by Eq. 1 and IC50 values are 
given in Tables 1 and 2. There is a noticeably greater left-right spread of curves for PhTX-343 and a leftward shift 
for late current inhibition curves as compared to peak current inhibition for both toxins.
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a 49-fold difference in late current IC50 value (at − 80 mV) between the most potent (0.1 μ M for α 1β 1γ δ and α 3β 4) 
and the least potent (4.9 μ M for α 7). The ranking order for nAChR affinity based on late current inhibition by 
PhTX-12 was: α 1β 1γ δ = α 3β 4 > α 4β 2 ≈ α 4β 4 > > α 3β 2 > α 7.
On the other hand, nAChR subunit combinations showed a slightly different profile for peak current IC50 
values for PhTX-12. The lowest peak current IC50 value at − 80 mV, observed for α 4β 4 nAChRs, was 1.65 μ M, 
increasing to 60 μ M for α 3β 2 nAChRs. The ranking order of potency in this case was: α 4β 4 > α 4β 2 > α 3β 4 > 
α 1β 1γ δ > α 7 > > α 3β 2. This reflects a strong time/use dependence for inhibition of α 1β 1γ δ, α 3β 4 and α 3β 2 by 
PhTX-12.
We also tested the mutated β 2 and β 4 subunits in combination with α 4 and α 3, respectively, for their inhibi-
tion by PhTX-12. There were no significant differences in IC50 values between α 4β 2 and α 4β 2(V253F) for peak or 
late current inhibition (Fig. 4C,D). For α 3β 4 and α 3β 4(F255V) there was no difference between the IC50 values for 
peak current inhibition (Fig. 4C), but for the late current inhibition it was increased by 3.3-fold (p < 0.0001) for 
α 3β 4(F255V) (Fig. 4D).
Comparison of the two PhTXs (at − 80 mV) with respect to peak current inhibition showed that PhTX-343 
was more potent at most of the nAChR subtypes, especially at α 3β 4 (33-fold), with α 1β 1δ γ being the only excep-
tion for which PhTX-12 was slightly more potent. For late current the two toxins were approximately equipotent 
at α 4β 2, α 3β 2 and α 7; PhTX-343 was more potent at β 4-containing subtypes; PhTX-12 was much more potent 
at α 1β 1γ δ (119-fold).
Voltage dependence of nAChR inhibition by PhTX-343 and PhTX-12. For each subunit combina-
tion, concentration-inhibition curves were obtained and IC50 values determined for both PhTXs at two additional 
holding potentials (− 60 mV and − 100 mV as shown in Tables 1 and 2).
PhTX-343 showed strongly voltage-dependent inhibition of heteromeric nAChRs, but it was 
voltage-independent for homomeric α 7 (Fig. 5). The extent of this depended on the subunits present. It appears 
that peak current inhibition by PhTX-343 was more sensitive to changes in VH (from − 60 mV to − 100 mV) on 
β 2-containing nAChRs than on β 4-containing receptors, whereas the opposite was found for late current inhi-
bition although this was less pronounced. For example, the peak current IC50 values for PhTX-343 inhibition of 
α 4β 2 and α 3β 2 at − 60 mV were decreased by 14- and 18-fold, respectively, at VH − 100 mV, whereas only a 3.3- 
and 3.8-fold decrease in IC50 was observed for α 4β 4 and α 3β 4 nAChRs, respectively.
In contrast to PhTX-343, PhTX-12 inhibition of peak current was voltage-independent for all nAChRs except 
for homomeric α 7 (Fig. 5). On the other hand, based on the late current IC50 values there was significant voltage 
VH (mV) n
PhTX-343 IC50 (95% CI), μM
Peak Late
α 4β 2
− 60 7 1.90 (1.01–3.60) 0.46 (0.28–0.75)
− 80 7 0.93 (0.41–2.09) 0.31 (0.18–0.54)
− 100 7 0.14 (0.09–0.22) 0.08 (0.049–0.132)
α 4β 2(V253F)
− 60 14 0.62 (0.30–1.28) 0.063 (0.045–0.089)
− 80 10 0.75 (0.46–1.23) 0.12 (0.06–0.23)
− 100 8 0.11 (0.07–0.17) 0.014 (0.011–0.016)
α 4β 4
− 60 9 0.97 (0.60–1.58) 0.17 (0.12–0.24)
− 80 9 0.35 (0.24–0.50) 0.065 (0.047–0.089)
− 100 6 0.29 (0.18–0.46) 0.027 (0.020–0.036)
α 3β 4
− 60 7 0.29 (0.21–0.40) 0.088 (0.065–0.120)
− 80 8 0.080 (0.062–0.104) 0.012 (0.010–0.014)
− 100 9 0.077 (0.059–0.102) 0.0077 (0.0063–0.0093)
α 3β 4(F255V)
− 60 7 0.31 (0.23–0.42) 0.074 (0.060–0.091)
− 80 9 0.038 (0.029–0.048) 0.012 (0.010–0.014)
− 100 8 0.017 (0.011–0.024) 0.005 (0.0036–0.0068)
α 3β 2
− 60 7 64.5 (7.8–532) 1.59 (1.20–2.11)
− 80 12 9.26 (5.90–14.6) 1.37 (1.12–1.69)
− 100 8 3.59 (1.58–8.19) 0.37 (0.29–0.48)
α 7
− 60 6 6.71 (5.39–8.35) 6.56† (5.30–8.12)
− 80 7 6.48 (5.12–8.21) 5.06† (3.95–6.48)
− 100 9 8.80 (6.92–11.18) 6.77† (5.44–8.42)
α 1β 1γ δ 
− 60 8 27.1 (19.1–38.4) 18.0 (12.8–25.4)
− 80 8 15.1 (9.5–24.0) 11.9 (9.2–15.4)
− 100 9 3.26 (2.54–4.17) 2.44 (1.50–3.97)
Table 1.  IC50 values for PhTX-343 inhibition of nAChR subunit combinations. IC50 values for PhTX-343 
inhibition of both peak and late current estimated from concentration-inhibition curves in Figs 2 and 4. †For α 7 
this is based on the area under the current trace as there was no stable late current.
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dependence, increasing as follows: α 4β 2 > α 3β 4 > α 3β 2 > α 7; but in all cases it was weaker than found for PhTX-
343, whereas inhibition was voltage-independent for α 4β 4 and α 1β 1γ δ (Fig. 5).
Recovery of nAChRs from inhibition by PhTX-343 or PhTX-12. We investigated the recovery rate 
of the peak and late current of nAChRs from inhibition by PhTX-343 and PhTX-12 at − 80 mV. In all experi-
ments we used approximately the ACh EC50 concentration, and following co-application of ACh with PhTX-343 
or PhTX-12 we applied ACh alone at 6 min intervals up to 6 times (i.e. 36 min range) (Fig. 6). PhTX-343 was 
co-applied at 10 μ M for α 4β 2, α 4β 4, α 3β 2 and α 3β 4, at 30 μ M for α 7, and at 100 μ M for α 1β 1δ γ to accommodate 
the different sensitivities. For all subunit combinations PhTX-12 was applied at 10 μ M.
Inhibition of homomeric α 7 and muscle-type nAChRs by PhTX-343 was reversible after 6 min washing in 
frog Ringer solution, while for heteromeric neuronal nAChRs it was irreversible (Fig. 6). For the latter the best 
recovery of peak current after six ACh applications (36 min) was obtained with α 3β 4 (to 82% of control), while 
VH (mV) n
PhTX-12 IC50 (95% CI), μM
Peak Late
α 4β 2
− 60 8 3.87 (1.47–10.16) 0.23 (0.14–0.38)
− 80 9 2.17 (1.30–3.64) 0.28 (0.17–0.45)
− 100 11 1.64 (0.74–3.67) 0.044 (0.030–0.064)
α 4β 2(V253F)
− 60 4 2.22 (1.44–3.42) 0.41 (0.28–0.60)
− 80 5 4.05 (2.22–7.36) 0.3 (0.25–0.35)
− 100 9 3.48 (1.40–8.70) 0.19 (0.13–0.27)
α 4β 4
− 60 9 1.21 (0.70–2.07) 0.25 (0.16–0.40)
− 80 12 1.65 (0.96–2.83) 0.29 (0.21–0.40)
− 100 9 2.77 (1.30–5.92) 0.19 (0.14–0.27)
α 3β 4
− 60 7 3.09 (2.13–4.47) 0.11 (0.08–0.14)
− 80 8 2.62 (1.71–4.01) 0.11 (0.08–0.15)
− 100 8 2.03 (1.22–3.36) 0.027 (0.022–0.033)
α 3β 4(F255V)
− 60 5 1.63 (0.74–3.60) 0.52 (0.30–0.90)
− 80 5 2.78 (1.13–6.84) 0.36 (0.26–0.50)
− 100 5 1.05 (0.54–2.05) 0.068 (0.044–0.105)
α 3β 2
− 60 9 65.2 (36.0–118.0) 3.20 (2.39–4.28)
− 80 12 60.6 (21.4–172) 2.57 (2.16–3.06)
− 100 10 74.4 (21.3–259.3) 1.38 (1.05–1.82)
α 7
− 60 12 18.7 (14.9–23.4) 8.32† (6.55–10.58)
− 80 12 11.1 (7.2–17.1) 4.92† (2.79–8.66)
− 100 10 12.1 (9.04–16.2) 5.02† (3.01–8.40)
α 1β 1γ δ 
− 60 9 3.16 (2.11–4.74) 0.070 (0.056–0.092)
− 80 11 6.18 (4.03–9.46) 0.10 (0.08–0.13)
− 100 8 5.02 (2.86–8.83) 0.071 (0.055–0.093)
Table 2.  IC50 values for PhTX-12 inhibition of nAChR subunit combinations. IC50 values for PhTX-12 
inhibition of both peak and late current estimated from concentration-inhibition curves in Figs 2 and 4. †For α 7 
this is based on the area under the current trace as there was no stable late current.
Figure 3. Alignment of amino acid sequences for the M1-M2 loop and M2 region in all of the nAChR 
subunits used in the present study. Residues expected to line the nAChR pore (termed rings below) are 
depicted in bold and numbered 1–8 starting at the extracellular terminus. F in ring 3 of r-β 4 (a difference that 
is conserved in other species including humans) is highlighted in orange, F and G in rings 5 and 6 (selectivity 
filter) of m-β 1 are highlighted in green and the positively charged residues at the external mouth of the pore in 
m-β 1, m-δ and m-γ are highlighted in blue.
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for α 4β 2, α 4β 4 and α 3β 2 it was very limited or absent. For late current, again α 3β 4 gave the best recovery (to 
69% of control).
Inhibition of nAChRs by PhTX-12 was fully or almost reversible after 6 min. Recovery of the peak current was 
complete for α 3-containing nAChRs, and of the late current for α 3β 2 and α 7. In all other cases 75% (for α 4β 4 
peak current) to 94% (for α 3β 4 late current) recovery, as compared to the control response, was achieved during 
the first ACh application after the removal of PhTX-12. Interestingly, the peak current for α 3β 4 during the first 
ACh application after removal of PhTX-12 was in fact larger than the control response in 4 out of 6 cells but the 
combined mean for all cells (119.4% control response, SEM 13.7%) was not significantly greater than control 
(p = 0.217).
Inhibition by PhTX-343 and PhTX-12 is largely non-competitive. To further study the mechanism 
of action by which PhTX-343 and PhTX-12 inhibit acetylcholine-evoked inward current in oocytes express-
ing nAChRs, we analysed the data obtained from the effects of a single PhTX concentration on acetylcholine 
concentration-response curves (Figs 7 and 8). The ACh EC50 values for peak current in the absence and presence 
of PhTX-343 for α 4β 2, α 4β 4, α 3β 2, α 3β 4, α 7 and α 1β 1γ δ, as well as for PhTX-12 at α 3β 4 and α 1β 1γ δ (for which 
potency was highest) are presented in Table 3.
PhTX-343 (1 μ M) caused a reduction of the maximum peak response to ACh, and no change in ACh EC50 in 
all heteromeric neuronal nAChRs was observed (Fig. 7A–D). However, for α 7 and α 1β 1δ γ receptors the inhibi-
tion of peak current by 30 μ M or 10 μ M PhTX-343, respectively, was surmountable by increasing ACh concen-
trations and the ACh EC50s were significantly (p < 0.05) increased (Table 3). For late current, the inhibition by 
PhTX-343 of all nAChRs, including α 7 and α 1β 1γ δ, was not surmountable by high ACh concentrations implying 
that the main inhibitory component was non-competitive.
Inhibition of peak current for both α 3β 4 and α 1β 1γ δ by 10 μ M PhTX-12 was surmountable by higher ACh 
concentrations, and in both cases the ACh EC50 was increased (p < 0.0001) by the toxin (Fig. 8A,B; Table 3). 
In contrast, the strong inhibition of the late current by 0.3 μ M PhTX-12 was insurmountable in both cases 
(Fig. 8C,D), again implying that the main inhibitory component was non-competitive.
Discussion
The results presented in this investigation show that the mechanism of inhibition and recovery of nAChRs in 
response to PhTX-343 is strongly influenced by their subunit combination. The nature of the β -subunit proved 
to be the main determinant for the inhibitory potency of PhTX-343 on nAChRs, based on our finding that 
Figure 4. The effect of M2 mutations β2(V253F) and β4(F255V) on PhTX-343 and PhTX-12 inhibition. 
Concentration-inhibition curves for PhTX-343 (A,B) and PhTX-12 (C,D) inhibition of α 3β 4 (blue ■ ),  
α 3β 4(F255V) (blue □ ), α 4β 2 (red ● ) and α 4β 2(V253F) (red ○ ) peak (A,C) and late (B,D) current. The ACh 
concentrations were 10 μ M for α 4β 2 and α 4β 2(V253F), and 100 μ M for α 3β 4 and α 3β 4(F255V). VH = − 80 mV. 
Curves are fitted by Eq. 1 and IC50 values are given in Tables 1 and 2.
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heteromeric β 4-containing nAChRs were more sensitive to PhTX-343 than β 2-containing receptors. This obser-
vation that β 4-subunits may have a higher sensitivity than β 2-subunits has been noted for other open-channel 
blockers of nAChRs such as cocaine18. On the other hand, nAChR inhibition by PhTX-12 did not depend strongly 
on the presence of a particular subunit type.
The late current IC50 value for α 3β 4 inhibition by PhTX-343, determined in the present work, was 88 nM at 
VH = − 60 mV. This value is in the same range as reported previously by a patch-clamp study of PC12 cells where 
an IC50 of 100 nM was obtained14. It has been shown that PC12 cells might express more than one subtype of 
neuronal nAChRs but α 3β 4 combinations are dominant19.
Results from our experiments show that inhibition of peak current by PhTX-343 is less effective than inhibi-
tion of late current, in agreement with Brier et al.8 and Liu et al.14. This variation in potency of PhTX-343 indicates 
that in order to interact with its binding site and inhibit nAChRs it is a prerequisite that the channel is in its open 
state8. This implies that inhibition occurs by open-channel blockage or by accelerating the desensitization kinetics 
of the channel. However, the additional voltage dependence of inhibition, demonstrated for all subunit combi-
nations but α 7, suggests the former to be most likely. Molecular modelling and photolabile cross-linking studies 
further support the hypothesis that PhTX-343 binds within the pore of the nAChR7,11. This is also corroborated 
by our data obtained from single-residue mutations in the M2 domains of β 2 (V253) and β 4 (F255). PhTX-343 
displayed enhanced potency at the mutant receptor containing β 2(V253F), and we interpret this by F providing an 
improved interaction with the aromatic moiety of PhTX-343 in the shallow part of the pore, while the polyam-
ine moiety retains interactions with the selectivity filter deeper in the pore. However, the inverse mutation (i.e. 
F255 → V255) in β 4 did not reduce the potency so it is likely that other factors, such as channel open-closed 
kinetics, may play a part. Similar point mutations in the M2 domain of β -subunits have been shown to change the 
sensitivity of nAChRs to other blockers such as cocaine18, substance P20, and nitric oxide21.
A striking feature of our data was the strong selectivity of PhTX-343 for heteromeric neuronal nAChRs over 
the muscle-type receptor. It is widely accepted that the pore of the nAChR is lined by eight rings of conserved 
amino acids which play a role in ion selectivity and conductance. These rings include (from extracellular to intra-
cellular): (1) a charged ring; (2) an outer hydrophobic ring; (3) a valine ring; (4) the equatorial leucine ring (gate); 
(5) a serine ring; (6) a threonine ring; (7) an intermediate negatively charged ring; and (8) an internal negatively 
charged ring (Fig. 3). We have previously proposed that PhTX-343 in its extended head-tail conformation can 
interact with both the valine and equatorial leucine rings via its hydrophobic head group, and with the serine and 
threonine rings deeper in the pore via its middle and terminal amine groups, respectively11. The low sensitivity 
of muscle-type nAChRs may be due to the presence of phenylalanine and glycine at the serine and threonine 
positions of rings 5 and 6, respectively, in β 1 (shaded green in Fig. 3), thereby reducing the interaction with the 
polyamine tail of PhTX-343. Additionally, the ratio between positively and negatively charged residues near the 
Figure 5. Voltage dependence of inhibition of nAChRs by PhTX-343 (A,B) and PhTX-12 (C,D) for peak  
(A,C) and late (B,D) current. The bars show IC50 (μ M) at VH of − 60, − 80 and − 100 mV. *(p < 0.05), **(p < 0.01), 
***(p < 0.001) and ***(p < 0.0001) indicate significant differences in the IC50 values for − 60 and − 100 mV 
(NS = not significantly different; p > 0.05).
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extracellular pore entrance may affect the access of PhTX-343 (with a charge of + 3) to the pore, and hence to its 
binding site. Heteromeric neuronal nAChRs will have two or three positively charged amino acids in this area 
depending on the number of β -subunits (each containing a lysine), while the muscle-type nAChRs have five posi-
tively charged residues in this region (1 lysine from β 1, 2 lysines from γ , and 1 lysine + 1 arginine from δ ) (shaded 
blue in Fig. 3). However, these hypotheses cannot explain the reduced potency of PhTX-343 at the homomeric 
α 7 receptor. Instead this may be as a result of the rapid desensitizing kinetics that significantly reduces the chance 
of PhTX-343 entering the open pore.
The above proposed mode of binding appears unlikely to have a major impact on PhTX-12 inhibition across 
the receptors studied here, and indeed PhTX-12 exhibited similar potency at the subunit combinations tested 
except for α 7 and α 3β 2 receptors that had a lower sensitivity to PhTX-12. These observations may relate to the 
previous suggestion that PhTX-12 adopts a folded conformation as a result of interaction between the terminal 
amine and the head region, thereby preventing access to the narrow part of the pore, suggesting binding to an 
alternative shallow site in the pore resulting in enhanced desensitisation rate8,11. Amino acid substitutions in this 
alternative binding region have been shown to influence desensitization rate22,23. α 7 receptors already have fast 
Figure 6. Recovery of responses to ACh following antagonism by PhTX-343 (A,B) and PhTX-12 (C,D) for 
peak current (A,C) and late current (B,D). A pre-toxin control response to ACh was obtained at − 6 min, the 
response at time 0 was in the presence of PhTX, while the responses from 6 min and onwards were applications 
of ACh only. ACh was applied at 10 μ M for α 4β 2 (green ● ), α 4β 4 (blue ■ ) and α 1β 1γ δ (orange ), 30 μ M for  
α 3β 2 (brown ▼ ) and 100 μ M for α 3β 4 (red ▲ ) and α 7 (purple ◆). PhTX-343 was applied at 10 μ M for α 4β 2,  
α 4β 4, α 3β 4 and α 3β 2, 30 μ M for α 7 and 100 μ M for α 1β 1γ δ . PhTX-12 was applied at 10 μ M for all subunit 
combinations. (E–G) Currents in response to ACh before PhTX application (black), ACh co-applied with PhTX 
(light grey), and ACh alone 6 min after co-application with PhTX (dark grey) for PhTX-343 inhibition of α 3β 4 
(E) and α 4β 2 (F), or PhTX-12 inhibition of α 4β 2 (G). VH = − 80 mV in all cases.
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desensitisation rates so binding of PhTX-12 may not augment this significantly, however, it is not clear why α 3β 2 
displays lower affinity for PhTX-12.
Comparison of the two toxins infers a clear preference for muscle-type nAChR for PhTX-12, while for neu-
ronal nAChR subtypes there are varying degrees of preference for PhTX-343. These results confirm our previous 
findings that the presence of the secondary amines prevent effective inhibition of muscle-type nAChRs in TE671 
cells5,8,13. In the present study, we show that PhTX-12 was 257-fold, 119-fold and 34-fold selective over PhTX-343 
on muscle-type nAChRs at VH of − 60 mV, − 80 mV, and − 100 mV, respectively. In comparison, our previous 
study on human muscle-type nAChRs in TE671 cells showed an 11-fold lower potency of PhTX-12 at this recep-
tor, but a similar 22-fold selectivity over PhTX-343 at − 100 mV8. It is likely that this difference in potency of 
PhTX-12 is due to differences in cell type and recording technique used in the two studies.
In the present work, the rate and extent of recovery from inhibition by PhTX-343 and PhTX-12 was contrast-
ing, and it was subunit-dependent for PhTX-343. Heteromeric neuronal nAChRs showed only poor recovery 
from inhibition by 10 μ M PhTX-343 even after six ACh applications over 36 min. Interestingly, α 3β 4 receptors 
recovered better than the other three combinations despite being the most potently inhibited, which may be 
linked to differences in open-closed channel kinetics that offer a higher probability for binding, but also for 
dissociation or slightly shallower binding due to F255 in the β 4-subunit, as also implied by the lower voltage 
dependence of inhibition. In contrast, muscle-type nAChRs and homomeric α 7 receptors showed almost full 
recovery upon the first ACh application after 6 min, most likely due to weaker interactions between PhTX-343 
and the nAChR pore. On the other hand, recovery from inhibition by PhTX-12 was complete or almost complete 
for all nAChRs upon the first ACh application after 6 min. The enhanced recovery from inhibition by PhTX-12 
may reflect the proposed shallower binding site11 from which the toxin can more readily dissociate, while poor 
Figure 7. Peak current ACh concentration-response curves in the absence (● ) or presence (■ ) of PhTX-
343 at 1 μM for α4β2, α4β4, α3β2 and α3β4, 10 μM for α1β1γδ and 30 μM for α7. Curves were fitted with 
Eq. 2 and EC50 values are given in Table 3. The grey symbols ( ) show the % control response for each ACh 
concentration in the presence of PhTX-343. VH = − 80 mV in all cases.
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Figure 8. Peak current (A,B) or late current (C,D) ACh concentration-response curves in the absence (● ) 
or presence (■ ) of PhTX-12 at 10 μM (peak current) or 0.3 μM (late current) for α3β4 and α1β1γδ. Curves 
were fitted with Eq. 2 and EC50 values are given in Table 3. The grey symbols ( ) show the % control response 
for each ACh concentration in the presence of PhTX-12. E-F: α 3β 4 currents in response to 100 μ M (E) or 1 mM 
ACh in the absence (black) and presence (blue) of 10 μ M PhTX-12. VH = − 80 mV in all cases.
[PhTX-343]
ACh EC50 (95% CI), μM
Control +PhTX-343
α 4β 2 1 μ M 13 (8.9–20) 22 (5.6–89)
α 4β 4 1 μ M 17 (8.4–36) 14 (7.8–25)
α 3β 4 1 μ M 78 (67–91) 89 (38–207)
α 3β 2 1 μ M 16 (12–20) 13 (9.4–18)
α 7 30 μ M 245 (198–304) 388* (265–568)
α 1β 1γ δ 10 μ M 25 (18–35) 54* (37–80)
[PhTX-12] Control +PhTX-12
α 3β 4 10 μ M 141 (113–175) 545**** (331–897)
α 1β 1γ δ 10 μ M 17 (15–20) 91**** (48–170)
Table 3.  ACh EC50 values in the absence and presence of PhTX-343 or PhTX-12. ACh EC50 values estimated 
from peak current concentration-response curves in the absence and presence of PhTX-343 or PhTX-12 shown 
in Figs 6 and 7. *p < 0.05 and ****p < 0.0001 when compared to the EC50 in the absence of toxin by an extra sum 
of squares F-test.
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recovery from blocking by PhTX-343 may be caused by its deep binding site in the pore where it may become 
‘entrapped’ during channel closure.
From previous studies, the mechanism of blocking of nAChR inward currents by PhTX analogues has been 
proposed to be non-competitive. Bixel et al.7 showed that α -bungarotoxin did not reduce the binding affinity 
of N3-Ph-PhTX-343-Lys to nAChRs of Torpedo californica, and even a slight increase was noticed with carba-
moylcholine. Likewise, inhibition of human muscle-type nAChRs by PhTX-343 and PhTX-12 was not influ-
enced by the ACh concentration8. Here, our finding that late current inhibition by PhTX-343 and PhTX-12 was 
not surmountable by increasing the ACh concentration further supports this observation. However, the weaker 
inhibition of peak current was reduced at high ACh concentrations for PhTX-343 at α 7 and α 1β 1γ δ as well as 
for PhTX-12 at both tested receptors (i.e. α 3β 4 and α 1β 1γ δ ), suggesting that there may be an element of weak 
competitive inhibition occurring before the stronger non-competitive use-dependent component masks it. An 
alternative and perhaps more likely explanation is that slower binding of PhTX as compared to that of ACh means 
that the faster peak current at high ACh concentrations will be much less affected by PhTX.
In conclusion, PhTX-343 potently inhibits ganglionic-type (α 3β 4) nAChRs with some selectivity over other 
heteromeric neuronal nAChRs, and with strong selectivity over homomeric α 7 and muscle-type nAChRs. In 
contrast to PhTX-343, PhTX-12 most potently inhibits muscle-type nAChRs but remains a weak inhibitor of 
homomeric α 7 receptors.
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